LV13225B - Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances - Google Patents

Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances Download PDF

Info

Publication number
LV13225B
LV13225B LV040079A LV040079A LV13225B LV 13225 B LV13225 B LV 13225B LV 040079 A LV040079 A LV 040079A LV 040079 A LV040079 A LV 040079A LV 13225 B LV13225 B LV 13225B
Authority
LV
Latvia
Prior art keywords
salts
pharmaceutical composition
composition according
estrogen
proline
Prior art date
Application number
LV040079A
Other languages
English (en)
Inventor
Matthias Rath
Aleksandra Niedzwiecki
Shrirang Netke
Vadim Ivanov
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Priority to LV040079A priority Critical patent/LV13225B/en
Publication of LV13225B publication Critical patent/LV13225B/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (9)

  1. LV 13225 Pretenzijas 1. Estrogēna un radniecīgo hormonu farmaceitiska kompozīcija kombinācijā ar farmaceitiskām kompozīcijām, kas paredzētas ar ārpusšūnu matriču deģenerāciju saistītu patoloģisku stāvokļu profilaksei un ārstēšanai.
  2. 2. Farmaceitiska kompozīcija saskaņā ar 1. punktu, kas satur askorbīnskābi vai askorbīnskābes sāļus.
  3. 3. Farmaceitiska kompozīcija saskaņā ar 1. punktu, kas satur estrogēnu, estradiolu, etinilestradiolu, estriolu, noretisteronu, linestrenolu un radniecīgos hormonus, kas satur lizīnu vai lizīna sāļus vai hidroksilizīnu vai hidroksilizīna sāļus.
  4. 4. Farmaceitiska kompozīcija saskaņā ar jebkuru no iepriekšējiem punktiem, kas satur prolīnu vai prolīna sāļus vai hidroksiprolīnu, vai hidroksiprolīna sāļus.
  5. 5. Farmaceitiska kompozīcija saskaņā ar jebkuru no iepriekšējiem punktiem, kas satur selēnu vai selēna sāļus, varu vai vara sāļus, dzelzi vai dzelzs sāļus un citus minerālus vai mikroelementus.
  6. 6. Farmaceitiska kompozīcija saskaņā ar jebkuru no iepriekšējiem punktiem, kas satur hondroitīna sulfātu, glikozaminoglikānus vai citus proteoglikānus vai glikoproteīnus, kas zināmi kā daļa no ārpusšūnu matrices.
  7. 7. Farmaceitisko kompozīciju saskaņā ar jebkuru no iepriekšējiem punktiem pielietojums dzimstības kontrolei, hormonu aizstājējterapijai, lai atvieglotu tipiskos ar menopauzi saistītos simptomus.
  8. 8. Farmaceitisko kompozīciju saskaņā ar vienu no 1. līdz 6. punktiem pielietojums osteoporozes, kardiovaskulāro slimību un citu saslimšanu profilaksei menopauzes laikā.
  9. 9. Farmaceitisko kompozīciju saskaņā ar vienu no 1.-6. punktiem pielietojums orālās formās, tabletēs, kapsulās vai jebkurās citās gremošanai, zemmēles, intravenozai, zemādas, intramuskulārai, transdermālai un jebkurai citai parentarālai lietošanai piemērotās formās.
LV040079A 2004-07-13 2004-07-13 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances LV13225B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LV040079A LV13225B (en) 2004-07-13 2004-07-13 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LV040079A LV13225B (en) 2004-07-13 2004-07-13 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances

Publications (1)

Publication Number Publication Date
LV13225B true LV13225B (en) 2005-04-20

Family

ID=35745290

Family Applications (1)

Application Number Title Priority Date Filing Date
LV040079A LV13225B (en) 2004-07-13 2004-07-13 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances

Country Status (1)

Country Link
LV (1) LV13225B (lv)

Similar Documents

Publication Publication Date Title
EP0641565B1 (en) Contraceptive and menstrual cycle controlling drug having oncostatic properties
Bray et al. Acute and chronic cutaneous reactions to ionizing radiation therapy
Patel et al. Use of pentoxifylline and tocopherol in radiation-induced fibrosis and fibroatrophy
EP3503921A1 (en) Use of cannabinoids in the treatment of multiple myeloma
Lyons et al. Pentoxifylline–a review of its use in osteoradionecrosis
JP2003520817A (ja) エストロゲンと組み合わせた選択的エストロゲン受容体モジュレータ
EP2018169B1 (en) Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
JP2019163318A (ja) 月経困難症および月経痛の管理のための方法
KR20190076014A (ko) 월경통 및 생리통의 관리방법
EP1453520B1 (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
US20050222100A1 (en) Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
LV13225B (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
RU2282449C2 (ru) Композиция с эстрогеном и другими гормонами, содержащая аскорбат, лизин, пролин и другие вещества
ZA200403776B (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances.
LT5239B (lt) Estrogeno ir kitų hormonų kompozicija su askorbatu, lizinu, prolinu ir kitomis medžiagomis
Wang et al. Effects of tibolone on the breast of postmenopausal women
Manni Endocrine therapy of metastatic breast cancer
RU2318508C2 (ru) Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы
Uchida et al. Inhibition by 9α-fluoromedoroxyprogesterone acetate (FMPA) against mammary carcinoma induced by dimethylbenz [a] anthracene in rats and angiogenesis in the rabbit cornea–comparison with medroxyprogesterone acetate (MPA)
RU2004125594A (ru) Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена
Jakesz Aromatase Inhibitors–The New Standard for Postmenopausal Women with Hormone-responsive Breast Cancer
Carter et al. Human chorionic gonadotropin (HCG) induction of apoptosis in breast cancer
Miller Drugs in the News in 1998
Tanne Vitamin A analogue protects against breast cancer